Authors

Latest:

Dr. Jonathan Henderson Discusses the Professional Need and Business Model for Men's Health Clinics

Jonathan Henderson, MD, urologist, Regional Urology, assistant director of clinical research, discusses how men's health clinics should be run by urologists.

Jonathan L. Silberstein, MD

Latest:

The Possibilities for Solid Tumor Modeling With 3D Printers Are Just Beginning

Three-dimensional printers are on the cusp of revolutionizing the way every doctor practices medicine.

Jonathan L. Wright, MD, MS, FACS

Latest:

Dr. Wright on Frontline Considerations in Locally Advanced Bladder Cancer

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.

Jonathan Ledermann, MD

Latest:

Dr. Ledermann on the Treatment Landscape for Rare Gynecologic Cancers

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the treatment landscape for patients with rare gynecologic cancers.

Jonathan Ledermann, MD, PhD

Latest:

Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer

Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.

Jonathan Mizrahi, MD

Latest:

Embracing Hepatic Artery Infusion Therapy for My Patients with Colorectal Cancer Liver Metastases

Jonathan N. Warner, MD

Latest:

Dr. Warner on the Future of Surgery for Patients With Prostate Cancer

Jonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.

Jonathan R. Strosberg, MD

Latest:

Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Jonathan R. Strosberg, MD, Moffitt Cancer Center

Jonathan Riess, MD

Latest:

Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC

Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Latest:

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center

Jonathan S. Batchelor

Latest:

Flaxseed Ineffective in Controlling Hot Flashes

Flaxseed had no effect on reducing hot flashes in postmenopausal women who reported experiencing 28 or more hot flashes per week.

Jonathan S. Berek, MD

Latest:

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Jonathan S. Zager, MD, Moffitt Cancer Center

Jonathan Strosberg, MD

Latest:

Dr. Strosberg Discusses Updates From the NETTER-1 Study

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).

Jonathan Strosberg, MD, Moffitt

Jonathan Ticku, MD

Latest:

Cloud Computing for Fellows

Cloud computing refers to Web-based programs that allow the user to store information in a central location, typically not the device being used to access the information (such as your laptop, desktop PC, or iPad).

Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Latest:

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Jonathan Tward, MD, PhD

Latest:

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.